<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"adenoma":1,
"ectopic":1,
"high cervical":1,
"hyperparathyroidism":1,
"parathyroid":1,
"parathyroidectomy":2,
"undescended":1,
"TSH-secreting pituitary tumors":1,
"cabergoline":1,
"heart failure":1,
"hyperthyroidism":2,
"Autoimmune thyroiditis":1,
"Hypothyroidism":2,
"Risk factors":2,
"Sterility":1,
"Uterine leiomyoma":1,
"beginners":1,
"learning curve":1,
"robot":2,
"robot training":1,
"robotic thyroidectomy":1,
"thyroidectomy":2,
"trainee":1,
"trainer":1,
"training program":1,
"American Thyroid Association (ATA) guidelines":1,
"disparities":1,
"papillary thyroid carcinoma":14,
"socioeconomic status":1,
"thyroid cancer":21,
"BRAF mutation":1,
"fine-needle aspiration biopsy":2,
"molecular marker testing":1,
"suspicious for papillary carcinoma":1,
"KMT2A":1,
"MLL":1,
"cytogenetics":1,
"diffuse large B-cell lymphoma":1,
"rearrangement":1,
"translocation":2,
"Ectopic thyroid tissue":1,
"bilateral thyroid goiter":1,
"the recurrent laryngeal nerve":1,
"thyroiditis":1,
"ultrasound":3,
"Chernobyl":1,
"ionizing radiation":1,
"Antiangiogenic drugs":1,
"VEGF inhibition":1,
"cabozantinib":2,
"medullary thyroid cancer":2,
"osteonecrosis of the jaw":1,
"Cervical neoplasm":1,
"Follow-up studies":1,
"Lymph nodes dissection":1,
"Papillary carcinoma":1,
"Recurrence":4,
"Lung cancer":1,
"Meta-analysis":6,
"Prognosis":7,
"Thyroid transcription factor 1":1,
"Cancer":4,
"Hormonal dysfunction":1,
"Late effects":1,
"Radiotherapy":3,
"fetal adenocarcinoma":1,
"genetic analysis":1,
"neuroendocrine carcinoma":1,
"α-fetoprotein":1,
"β-catenin":1,
"Head and neck":1,
"Thyroglossal duct cyst":1,
"Xanthogranulomatous inflammation":1,
"F-18 FDG PET/CT":1,
"FNAB":1,
"Inconclusive":1,
"Thyroid nodule":7,
"BRAF":6,
"Thyroid hormone receptor":1,
"miRNA":1,
"Laryngopharyngeal reflux":1,
"Larynx":1,
"Proton pump":1,
"Thyroid cartilage":1,
"Haplotype":1,
"IL-18":1,
"Polymorphism":1,
"Alström syndrome":1,
"Follicular variant of papillary thyroid carcinoma":1,
"Thyroid goitre":1,
"early detection":1,
"overdiagnosis":1,
"papillary":2,
"stage specific trends":1,
"thyroid cancer incidence trends":1,
"Inherited syndromes":1,
"Paraganglioma/pheochromocytoma":1,
"microchimerism":1,
"pregnancy":1,
"women":1,
"Immunohistochemistry":3,
"TSGA13":1,
"Testis-specific":1,
"Tissue array":1,
"Tumor":1,
"breast cancer":3,
"population-based study":1,
"Acromegaly":1,
"Goiter":1,
"Thyroid autoimmunity":1,
"Thyroid nodules":2,
"68Ga-DOTA-LAN":1,
"68Ga-DOTA-TOC":1,
"Somatostatin receptor PET imaging":1,
"Adverse events":2,
"Mortality":1,
"Relative risk":1,
"Sorafenib":3,
"Tyrosine kinase inhibitors":3,
"TITF1":1,
"TITF2":1,
"Bethesda classification":1,
"Cytopathology":1,
"Follicular":2,
"Nodule":2,
"Thyroid":9,
"Clinicopathological":1,
"Guidelines":1,
"Low-risk DTC":1,
"Surgeon experience":1,
"Thyroid remnant ablation":1,
"Thyroid remnant size":1,
"BRAF gene":1,
"Deletion":1,
"Papillary thyroid cancer":3,
"Rare mutation":1,
"Clear cell carcinoma of the thyroid":1,
"Next generation sequencing (NGS)":1,
"TP53":3,
"TSHR":1,
"Nontoxic autonomous nodule":1,
"Thyroid fine needle aspiration":1,
"Thyroid malignancy":1,
"Toxic nodule":1,
"cost-effectiveness analysis":1,
"epidemiology":2,
"thyroid neoplasm":1,
"ultrasonography":4,
"Classic and follicular variant papillary thyroid carcinoma":1,
"Histopathological features":1,
"Anaplastic thyroid cancer":1,
"EMT":1,
"Invasion":2,
"MART-10":1,
"Migration":1,
"Vitamin D":1,
"Amyloid":1,
"Calcitonin":1,
"Endocrine":2,
"Medullary thyroid carcinoma":4,
"iodine refractory":1,
"metastatic":1,
"ETV6-NTRK3":1,
"RAS":1,
"RET/PTC":1,
"radiation-exposed papillary thyroid carcinomas":1,
"sporadic pediatric papillary thyroid carcinomas":1,
"integrin αvβ3":1,
"mesenchymal stem cells":1,
"tetrac":1,
"thyroid hormones":1,
"tumour stroma":1,
"MicroRNA":3,
"Staging":1,
"High resolution melt analysis":1,
"MEN2A":1,
"MEN2B":1,
"Multiple endocrine neoplasia":1,
"RET proto-oncogene":2,
"FISH":1,
"Hashimoto’s thyroiditis":3,
"Plasma cell leukemia":1,
"TSC":1,
"computed tomography":1,
"incidentaloma":1,
"TSH":1,
"conversion":1,
"deiodinase":1,
"l-T4 therapy":1,
"levothyroxine":1,
"thyroid hormone replacement":1,
"triiodothyronine":1,
"B-Raf":1,
"Colorectal cancer":2,
"Oncogene-induced senescence":1,
"Rac1b":1,
"Tumor progression":1,
"Undifferentiated thyroid carcinoma":2,
"VEGF":2,
"miR-205":1,
"carcinoma":1,
"Neutrophil-to-lymphocyte ratio":1,
"Platelet-to-lymphocyte ratio":1,
"Thyroid neoplasms":4,
"Bethesda reporting system":1,
"Hurthle cells":1,
"diagnosis":2,
"follicular neoplasms":1,
"malignant lesions":1,
"thyroid cytology":1,
"Malignant struma ovarii":1,
"Molecular":1,
"Ovary":1,
"cell signaling":1,
"glucose":1,
"metformin":2,
"oncosis":1,
"Adiposity":1,
"differentiated thyroid cancer":3,
"targeted therapy":2,
"tyrosine kinase inhibitor":1,
"Acoustic radiation force impulse":1,
"Shear wave elastography":2,
"Shear wave velocity":1,
"Adenomatous hyperplasia":1,
"Brenner tumor":1,
"Mucinous cystadenoma":1,
"Serous cystadenoma":1,
"Struma ovarii":1,
"Strumal carcinoid":1,
"MAPK pathway":1,
"Tob1":1,
"radiosensitivity":1,
"PIK3R2":1,
"miR-126":1,
"Immunohistochemical expression":1,
"Pancreatic adenocarcinoma":1,
"Prognostic biomarker":1,
"Pyruvate muscle kinase isoenzyme 2":1,
"cytology":2,
"discrepancy":1,
"solid":1,
"Ablation":1,
"Cost-effectiveness":1,
"Hypothyroid":2,
"Radioiodine":1,
"Thyrotropin alfa":1,
"AKT":2,
"ERK":1,
"Thyroid carcinoma":2,
"cell signalling pathway":1,
"minimally invasive surgery":2,
"neck surgery":1,
"retroauricular approach":1,
"3-D ultrasound":1,
"(131)I ablation":1,
"Ablación con(131)I":1,
"Ampliamente invasivo":1,
"Carcinoma folicular":1,
"Cirugía":1,
"Diferenciación":1,
"Differentiation":2,
"Follicular carcinoma":3,
"Invasive":1,
"Invasión":1,
"Minimally invasive":1,
"Mínimamente invasivo":1,
"Surgery":1,
"Tiroides":1,
"Clinical metabolomics":1,
"Follicular lesions":1,
"Formalin-fixed paraffin-embedded tissue specimen":1,
"Gas chromatography/mass spectrometry":1,
"structured reporting":1,
"thyroid imaging":1,
"Adverse effects":1,
"Complications":1,
"Differentiated thyroid carcinoma":2,
"I-131":1,
"Radioactive iodine":2,
"Second primary malignancies":1,
"Contrast-enhanced ultrasound":1,
"Logistic models":1,
"Thyroid microcarcinoma":1,
"Japanese patients":1,
"lenvatinib":4,
"progression-free survival":1,
"treatment efficacy":1,
"Acrylamide":1,
"Bioassay":1,
"Glycidamide":1,
"Mice":1,
"Rats":1,
"Tumorigenicity":1,
"Cáncer diferenciado de tiroides":1,
"Instilación intraductal":1,
"Intraductal instillation":1,
"Radioiodine induced sialadenitis":1,
"Sialadenitis":1,
"Sialoadenitis":1,
"Sialoadenitis inducida por radioyodo":1,
"Afirma":1,
"molecular test":1,
"thyroid FNA":1,
"Fused gene":1,
"Next-generation sequencing":1,
"RET gene":1,
"RET/PTC rearrangement":1,
"RET/PTC1ex9":1,
"Anaplastic":2,
"Brain":1,
"Metastasis":3,
"Skull":1,
"Histopathological characteristics":1,
"Encapsulated low-grade follicular cell–derived thyroid carcinoma":1,
"Hurthle cell carcinoma":1,
"Vascular invasion":1,
"MKT 077":1,
"Mitochondria":1,
"Thyroid cancer, follicular":1,
"Thyroid cancer, papillary":1,
"extranodal extension":1,
"survival":1,
"Pathology Section":1,
"VE1":1,
"heterogeneity":1,
"categorizing":1,
"head and neck ultrasound":2,
"sonography":1,
"IRE1/XBP1":1,
"STF-080310":1,
"tamoxifen":1,
"capsular invasion":1,
"extracapsular extension":1,
"extrathyroidal extension":1,
"Atipia de significado incierto":1,
"Atypia of undetermined significance":1,
"Bethesda":1,
"Fine-needle aspiration":1,
"Nódulo tiroideo":1,
"Punción-aspiración con aguja fina":1,
"OXPHOS":1,
"cancer metabolism":1,
"cancer stem cells":1,
"chemoresistance":1,
"Hürthle cell carcinoma":1,
"Mutation":1,
"Next generation sequencing":1,
"Oncocytic follicular carcinoma":1,
"PTEN":1,
"Angiogenesis":2,
"E7080":1,
"Japanese":1,
"Phase 1":1,
"Safety":1,
"Guinea pig":1,
"Hyperadrenocorticism":1,
"Insulinoma":1,
"Thyroid gland tumours":1,
"High-dose I-131 ablation therapy":1,
"Therapeutic failure":1,
"Thyroglobulin doubling time":1,
"Differentiated":1,
"Medullary":1,
"Vandetanib":1,
"PTC":1,
"melanoma":1,
"CT":1,
"MRI":1,
"incidental":1,
"Intraoperative parathyroid level":1,
"Scintigraphy":1,
"follicular thyroid cancer":1,
"gene fusion":1,
"peroxisome proliferator-activated receptor gamma":1,
"pioglitazone":1,
"Cervical mass":1,
"Ex utero intrapartum treatment procedure":1,
"Germ cell tumour":1,
"Malignancy":3,
"Polyhydramnios":1,
"Teratoma":1,
"Acquired cystic disease":1,
"Hereditary":1,
"Leiomyomatosis":1,
"Renal cell carcinoma":2,
"Thyroid-like follicular":1,
"Tubulocystic":1,
"Cutaneous metastasis":1,
"undifferentiated tumor":1,
"Cancer screening":1,
"Dépistage":1,
"General practitioner":1,
"Guideline adherence":1,
"Military medicine":1,
"Médecin généraliste":1,
"Médecine militaire":1,
"Recommandations":1,
"BRAFV600E papillary thyroid cancer pre-clinical model":1,
"MCL1 and P16/CDKN2A somatic copy number":1,
"microenvironment":1,
"vemurafenib resisatnce":1,
"Ferredoxin reductase":1,
"biomarker":1,
"chemoradiation therapy":1,
"esophageal squamous cell carcinoma":1,
"Anaplastic thyroid carcinoma":1,
"Bcl2":1,
"TRAIL":1,
"apigenin":1,
"biochemical alterations":1,
"thyroxine withdrawal":1,
"Carcinome médullaire de la thyroïde":1,
"Pheochromocytoma":1,
"Phéochromocytome":1,
"Proto-oncogène RET":1,
"PUBLIC HEALTH":1,
"esophageal recurrence":1,
"medullary carcinoma":1,
"Akt/FOXO1/Bim pathway":1,
"FOXO1":1,
"apoptosis":1,
"proliferation":1,
"siRNA":2,
"Follicular cell carcinoma":1,
"Nyctereutes procyonoides, raccoon dog":1,
"serum thyroid hormone":1,
"thyroid glands":1,
"Cholangiocarcinoma":1,
"Extra-hepatic malignancies":1,
"Hepatitis C virus":1,
"Hepatocellular carcinoma":1,
"Neoplasm":1,
"Pancreatic cancer":1,
"BIBF 1120":1,
"nintedanib":1,
"STATISTICS &amp":1,
"RESEARCH METHODS":1,
"Cricotracheal invasion":1,
"Laryngeal invasion":1,
"Tetris":1,
"Tracheal invasion":1,
"Artery/arteries":1,
"lung cancer surgery":1,
"sarcoma":2,
"thoracic inlet (TI)":1,
"Breast neoplasms":2,
"Dairy products":1,
"Risk assessment":2,
"Case-control studies":1,
"Human epidermal growth factor receptor 2":1,
"Second primary neoplasms":1,
"retinoblastoma binding protein 2":1,
"soft agar colony formation assay":1,
"transwell chamber assay":1,
"bone metastases":1,
"double primary cancers":1,
"intrahepatic cholangiocarcinoma":1,
"therapy":1,
"KIT":1,
"PDGFRA":1,
"Small cell carcinoma":1,
"urinary bladder":1,
"Angiogenesis inhibitors":1,
"Hypercalcaemia":1,
"Primary hyperparathyroidism":1,
"Autoimmune thyroid diseases":1,
"Pollution":1,
"Follicular thyroid carcinoma":1,
"Response evaluation":1,
"Hemoptysis":1,
"Hypertrophic osteoarthropathy":1,
"Paraneoplastic syndrome":1,
"Poorly differentiated thyroid cancer":1,
"BRAF V600E mutation":1,
"thyroid papillary carcinoma (PTC)":1,
"Microcarcinoma":1,
"Thyroid-stimulating hormone":1,
"Tumor size":1,
"Bethesda system":1,
"Fine-needle aspiration cytology":1,
"Histopathology":1,
"Malignancy rate":1,
"Neurotoxicity":1,
"PC12":1,
"TBBPA derivatives":1,
"Cyclophosphamide":1,
"Systemic sclerosis":1,
"Lung carcinoma":1,
"Magnifying colonoscopy":1,
"Pedunculated-type T1 colorectal carcinoma":1,
"CT, computed tomography":1,
"FTC, follicular thyroid carcinoma":1,
"MRI, magnetic resonance imaging":1,
"Jaw tumors":1,
"metastasis to jaws":1,
"oral cavity":1,
"kinase inhibitors":1,
"Kidney neoplasms":1,
"Kidney tumor":1,
"Renal":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2015年12月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
